Latest News

If your TFSA balance is below the average for Canadians in their early 50s, these two proven dividend stocks could help you close the gap over time.

These stocks should be attractive to buy on dips.

A Berkshire acquisition from 10 years ago gives the Oracle of Omaha's conglomerate exposure to the data center proliferation trend.

Financial services company Triumph Financial (NYSE:TFIN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.9% year on year ...

Taiwan Semiconductor has a specific advantage over other AI stocks.

Sale executed under pre-scheduled Rule 10b5-1 plan reduced his equity stake by just 1%, leaving him with $496.55 million in remaining holdings.

Fortis is a North American utility stock that boasts a 52-year track record of rising dividends and resilience in all market conditions.

BCE (TSX:BCE) and Telus (TSX:T) are towering dividend payers, but there are less choppy value bets out there.

SGDM outperformed over the past year but carries deeper drawdowns. GLD offers lower volatility and greater liquidity with $129.2 billion in assets.

The social media giant seeks artificial superintelligence for everyone.

At first glance, its numbers were impressive.

Make your $7,000 TFSA contribution work for decades by buying three Canadian compounders you won’t panic-sell in a downturn.

MSCI's second-quarter earnings were fine, but the stock is selling off after missing analysts' expectations.

This TFSA stock would be more compelling for a high yield on a meaningful pullback.

Space Exploration Technologies (NASDAQ:SPCX) stock might be a nice draw to new, young investors looking to start off a TFSA wealth-building journey.

VOOG delivered stronger 1-year returns, but VUG's lower 0.03% expense ratio and $379B in assets offer cost advantages for long-term investors.

Reiff exercised fully vested options under a pre-arranged trading plan adopted nearly a year ago, reducing her direct holdings by 18% while retaining $1.51 million in equity.

The iShares ETF invests in international markets outside the U.S., while the Vanguard fund offers global exposure including the U.S.

Med Tech revenue surged 16.7% as company shifts toward higher-margin products.

Net sales hit $2.4B with 14.7% growth driven by larger customer gains.

Net income surged 45% as revenue hit a decade high of $24.8 billion.

EPS surged 25% as revenue growth and efficiency gains accelerated across all segments.

Record revenue and earnings driven by M&A surge and AI infrastructure investment cycle.

Net income surged 27% as investment banking and trading revenue hit record levels.

Another restructuring is rattling nerves days before earnings. The cash flow math, however, tells a calmer story.